Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma

Completed

Conditions studied: Multiple Myeloma

In brief

The purpose of this study is to understand if small proteins found on the surface of myeloma cells (called CXCR4 and CD47) or inside the myeloma cells (Pim kinases, sphingolipids, and pS6) can predict how patients will respond to chemotherapy-treatment and if a small molecule inside the myeloma cells (called Pim kinase) can be used as a treatment target for myeloma. A sample from the bone marrow biopsy (a small amount of tissue removed from the body for laboratory testing) and aspirate (a small amount of fluid is removed from the body for laboratory testing) that had been done before the subject entered this study will be provided for research purposes. Based on preliminary data, it is hypothesized that CXCR4, CD47, sphingolipids, and Pim kinases could be used as prognostic/predictive markers and that Pim kinase inhibitors provide a new agent for the treatment of multiple myeloma.

Key facts

Study ID

NCT01410981

Run by

Medical University of South Carolina

People needed

73

Starts

2011-08-01

Expected to finish

2014-06-01

Last updated by the study team

2018-04-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A diagnosis of multiple myeloma or possible multiple myeloma who will have a bone marrow biopsy and aspirate
• Planned therapy with standard chemotreatment for multiple myeloma
• Laboratory data such as calcium, beta 2-microglobulin, albumin, creatinine and bone survey available for staging purpose.
• ≥18 years old

You may not qualify if…

• < 18 years old
• Patients who will not receive chemotreatment
• Patients whose treatment records are not available

Where it is running

• Medical University of South Carolina — Charleston, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.